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Mutated ASXL1 and number of somatic mutations as
possible indicators of progression to chronic
myelomonocytic leukemia of myelodysplastic 
syndromes with single or multilineage dysplasia
Myelodysplastic syndromes (MDS) are heterogeneous
clonal disorders characterized by ineffective
hematopoiesis and transformation in acute myeloid
leukemia (AML).1 However, disease progression is not
always to overt AML; MDS may develop myeloprolifera-
tive features and move to overlap-diseases [MDS/myelo-
proliferative neoplasms (MPN)],  such as chronic
myelomonocytic leukemia (CMML).
Some authors reported unexpected transformation of
de novo MDS to CMML independently of the presence of
relative monocytosis (>10%) at initial diagnosis of
MDS.2,3 In these reports, apart from an evident increase in
total white blood cell count (WBC) and monocytosis,
alterations of other clinical parameters and/or cytogenet-
ic and molecular abnormalities were not associated
directly with progression.3 Deep sequencing demonstrat-
ed the high frequency of somatic mutations in MDS as
well as the acquisition of additional mutations during dis-
ease history.4,5 Some somatic mutations are often shared
by MDS and MDS/MPN and contribute in different ways
to the prognosis of these disorders.6-8
Padron et al.4 identified a similar pattern of mutations
at diagnosis and in the myeloproliferative stage of MDS
patients that transformed to CMML, with maintained
variant allele frequency (VAF). The acquisition of new
mutations was nevertheless evident at progression
(ETV6, NRAS, CBL, and RUNX1) and differently to this,
but in the same line of multi-step clonal evolution, it was
observed that MDS progressing to AML acquired muta-
tions of RUNX1, ETV6, PHF6, NRAS and KRAS.5
Here, on a molecular level, we describe a cohort of
lower risk MDS patients who evolved to CMML. All con-
secutive cases diagnosed at Azienda Ospedaliero
Universitaria Careggi (Florence, Italy) as MDS in accor-
dance with World Health Organization (WHO) 2008 cri-
teria between April 2010 and September 2016 were
revised. Out of 360 cases analyzed, we identified 9
patients reclassified with revised WHO 20169 presenting
a diagnosis of MDS with single lineage dysplasia (MDS-
SLD) or MDS with multilineage dysplasia (MDS-MLD)
who progressed to overt CMML after variable follow-up
periods  (referred as Group 1) (Table 1). In all patients,
absolute and relative monocytosis was absent during the
entire duration of MDS and the median time to CMML
transformation was 21 months (range 10-41) (Table 1).
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Figure 1. Representation of mutations and variant allele frequency (VAF) (%) in the paired DNA samples of the myelodysplastic syndrome (MDS) and chronic
myelomonocytic leukemia (CMML) phases in the Group 1 of patients. Each graph represents cases #1 to #9 of Group 1. Genes are color coded and VAFs (y-
axis) and protein change (x-axis) are represented for each variant. Our panel gene was as follows (only the first nine genes were mutated in  Group 1 of patients
at MDS diagnosis): ASXL1, EZH2, RUNX1, SETBP1, SF3B1, U2AF1, SRSF2, TET2, DNMT3A, TP53, ETV6, NPM1, FLT3, CBL, CSF3R, CEBPA, IDH1, IDH2, JAK2,
MPL, CARL.
Paired DNA samples of the MDS and CMML phases
were isolated in all 9 cases. Bone marrow (BM) mononu-
clear cells were collected and cryopreserved at diagnosis
(MDS phase) and at transformation (CMML phase).
Informed consent was provided in accordance with the
Declaration of Helsinki and local ethics committee
approval. Twenty-two candidate genes were selected for
sequencing analysis (See Online Supplementary Appendix
for methods), referred to in literature as those most fre-
quently mutated in MDS and CMML:10-12 ASXL1, EZH2,
TP53, SF3B1, U2AF1, SRSF2, TET2, DNMT3A, ETV6,
RUNX1, NPM1, FLT3, CBL, SETBP1, CSF3R, CEBPA,
IDH1, IDH2, JAK2, MPL, CARL, NRAS. Patients' charac-
teristics are presented in Table 1. In brief, 5 were males,
and the median age at diagnosis was 67 years (range 56-
76 years). At diagnosis, 4 patients had MDS-SLD and 5
patients had MDS-MLD. At transformation, 3 patients
presented a CMML-0, 4 patients a CMML-1, and 2
patients a CMML-2 according to the WHO 2016 classifi-
cation. WBC, absolute monocyte count (AMC) and blast
count in CMML phase were statistically higher than in
MDS phase (mean WBC 3.64×109/L vs. 13×109/L,
P=0.001; AMC 0.21×109/L vs. 1.6×109/L, P=0.004; blast
count 0% vs. 6%, P=0.0001). There was no significant
statistical difference in  hemoglobin level (10.85 g/dL vs.
9.7 g/dL, P=0.42) or platelet count (147×109/L vs.
86×109/L, P=0.11) between the MDS and CMML phases.
After the initial diagnosis of MDS, all patients were treat-
ed exclusively with erythropoiesis-stimulating agents,
and all patients with and without stable disease were fol-
lowed every three months. In both phases, 5 patients
presented a normal karyotype, one patient a monosomy
7, one patient a trisomy 8, and one patient a trisomy 14.
Only case #1 presented a new trisomy 8 at progression
(Table 1). After sequencing, coverage across targeted
regions was 2500X (minimum 316 and maximum 9877).
In the MDS phase, somatic mutations were identified in
9 genes, resulting in 29 variants. All mutations were het-
erozygous, and comprised 10 missense, 10 nonsense, and
9 frameshift mutations. Eight of the 9 CMML-progressing
cases presented three mutations or more (median num-
ber of mutations: 3, range 2-5) (Online Supplementary
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Table 1. Clinical and cytogenetic characteristics of myelodysplastic syndrome patients that progress to  chronic myelomonocytic leukemia.
Case# 1 2 3** 4 5 6 7 8 9
Age 63 56 70 76 63 67 71 72 64
Sex Female Female Male Male Male Male Male Female Female
Time to transformation CMML (months) 20,8 12,1 21,2 39,2 10,5 17,0 20,6 41,6 27,6
*WHO classification MDS-MLD MDS-MLD MDS-SLD MDS-MLD MDS-MLDMDS-SLD MDS-SLD MDS-SLD MDS-MLD
IPSS/IPSS-R Low / Int-1 / Low / Int-1 / Int-1 / Low / Int-1 / Low / Low / 
Very low Low Very low Int Int Very low Int Very low Low
WBC count (x109/L) MDS 4.04 2.24 10.3 2.79 5.7 3.64 1.74 4.54 2.40
CMML 13.2 12.1 59.1 24.4 13 4.9 33.3 12.1 4.5
ANC count (x109/L) MDS 2.2 1.7 6.8 2.01 3.4 2.1 1.2 2.66 1.9
CMML 9.4 8.2 56.2 10.5 8.7 2.7 26.4 6.3 2.7
AMC count (x109/L) MDS 0.48 0.12 0.72 0.25 0.30 0.44 0.06 0.17 0.03
CMML 2.1 1.6 1.48 8.6 3.60 1.60 5.3 1.4 1.5
Monocytes (%) MDS 9.4 5.4 6.9 8.9 5.2 9.3 3.5 3.7 1.3
CMML 15.9 13.2 2.5 35.2 27.7 32.6 16 11.5 33.3
BM blasts (%) MDS 0 0 0 4 4 0 4 0 0
CMML 12 4 6 9 19 5 9 4 0
Hemoglobin (g/dL) MDS 11.2 12.4 8 5.6 14.7 10.8 10.4 10.5 13.3
CMML 7.4 9.7 8.8 7.2 15 11.1 9.1 10.1 12.3
Platelets (x109/L) MDS 145 78 173 208 86 145 37 354 149
CMML 80 82 94 110 45 142 30 86 104
Cytogenetics MDS Normal -7 Normal +14 +8 Normal Normal Normal Normal
CMML +8 -7 Normal +14 +8 Normal Normal Normal Normal
Organomegaly MDS No No No No No No No No No
CMML Yes No Yes Yes Yes No No Yes No
Time AML evolution 8.8 NA NA NA 6.9 NA NA 3.1 NA
(months)
*At initial diagnosis of myelodysplastic syndromes (MDS). **Criteria for diagnosis of chronic myelomonocytic leukemia (CMML) for case #3 are not completely fulfilled;
the percentage of monocytes is less than 10% [level required in the World Health Organization (WHO) 2016 definition of CMML]. This patient cannot be diagnosed as atyp-
ical chronic myeloid leukemia (CML) because the first condition according to the WHO for such a diagnosis is not satisfied:  “PB leukocytosis due to increased numbers
of neutrophils and their precursors (promyelocytes, myelocytes, metamyelocytes) comprising ≥10%  of leukocytes”. Myelodysplastic syndromes/myeloproliferative neo-
plasms (MDS/MPN)-unclassifiable is also not applicable because absolute monocyte count (AMC) in the progression to MDS/MPN was more than 1000/uL. MDS-SLD:
myelodysplastic syndrome with single lineage dysplasia; MDS-MLD: myelodysplastic syndrome with multilineage dysplasia; IPSS: International Prognostic Score System;
IPSS-R: revised International Prognostic Score System;  Int-1: intermediate-1; Int: intermediate; WBC: white blood cells; ANC: absolute neutrophil count;  BM: bone marrow;
AML:  acute myeloid leukemia; NA: not applicable; PB: peripheral blood.
Figure S1). The mutational analysis of the CMML phase
confirmed the presence of all the 29 variants found at
diagnosis (Figure 1). In general, mutation VAF did not
change significantly, while some mutated clones were
marginally expanded during progression. An acquisition
of two missense variants was presented in the CMML
samples: case #3 with a new variant of the DNMT3A
gene and case #7 with a new variant of the gene NRAS
(Figure 1). In our cohort of patients, the acquisition of
new somatic mutations was not closely correlated with
progression, as  7 of the 9 cases studied did not acquire
new mutations. We then compared the mutational pro-
file of Group 1 with a second cohort of lower risk MDS
patients that did not present CMML transformation or
progression to higher risk MDS or AML (referred as
Group 2). Clinical data of Group 2 are summarized in
Online Supplementary Table S1. Groups 1 and 2 were
matched by age, sex and International Prognostic Scoring
System (IPSS) risk; Group 2 had a longer OS than Group
1 (67 vs. 38 months) (Online Supplementary Figure S2).
After sequencing of Group 2, coverage across the target-
ed regions of 3441X (minimum 410 and maximum
11401) was obtained. Thirteen cases (28%) did not pres-
ent any mutation in the 22 genes analyzed, and 33 cases
(72%) presented at least one mutation (median number
of mutations: 1, range 1-3). The first important observa-
tion is that Group 1 cases presented with a higher num-
ber of mutated genes: 88% cases of Group 1 showed 3 or
more mutations compared with 2 cases (4%) of Group 2
(Figure 2 and Online Supplementary Figure S1). The second
observation is that the most frequently mutated genes in
Group 1 were ASXL1 and TET2 that were mutated in all
cases and in 6 of 9 cases, respectively (Figure 2A).
Consistent with reports in literature, TET2, SF3B1 and
DNMT3A were the most frequently mutated genes in
Group 2 cases (19%, 24% and 28%, respectively),10,11
while ASXL1was present in only 3 cases (7%): in 2 cases
as an isolated mutation and in one case in combination
with TET2 and SRSF2 (Figure 2B). The latter case has
been censored because the patient received an early
hematopoietic stem cell transplant, and therefore it was
not possible to evaluate progression. Group 1 cases
shared the constant presence of ASXL1 mutations. Based
on average sequencing depth versus VAF, ASXL1 muta-
tions in Group 1 appear both as clonal and subclonal.
Moreover, VAF of ASXL1 in cases #3 and #8 did not vary
significantly while other mutations presented in the same
samples increased in size (Figure 1). It seems that, togeth-
er with the presence of ASXL1 mutations, the increase in
size of other clones could be related to the disease pro-
gression. An ASXL1 mutation is present in 45% of
CMML cases and has an adverse prognostic impact on
OS.12,13 TET2 mutations, the second most frequent in
Group 1, are widely prevalent in CMML (46%) and their
prognostic relevance remains unclear;14  in our series TET2
mutations were not present in any of our cases that pro-
gressed from MDS to CMML. Co-mutation of ASXL1
and TET2 is associated with very poor survival in
CMML.14 In order to evaluate the weight of ASXL1 and
TET2 mutation positive clones in this peculiar MDS-to-
CMML progression, we compared VAF data of the MDS
and CMML phases using the paired sign test. VAF of
ASXL1was significantly higher in CMML than in the cor-
responding MDS phase (42% vs. 29%, respectively,
P=0.039) while VAF of TET2 was not significantly varied
in either  phase (55% vs. 46%, respectively, P=0.38)
(Online Supplementary Figure S3A and B), suggesting that
early presence and increase in the burden of mutated
ASXL1 during progression of the disease to myeloprolif-
erative features have a prominent and determining role.
It should  be stressed that the presence of ASXL1 muta-
tion was a rare event (7%) in matched lower risk MDS
cases of Group 2 without any kind of progression.
Although our study was limited by the number of cases
evaluated, no significant changes were observed in the
mutation profile during progression to CMML. Although
the presence of acquired mutations in other genes not
included in this study cannot be excluded, nevertheless,
our observations strongly suggest  that a “pre-CMML
state” could possibly be identified. All “pre-CMML” cases
were characterized by worsening anemia that required
treatment, in line with the role of ASXL1 in erythro-
poiesis.15 These very particular “pre-CMML”-MDS cases
seem to be well characterized by enhanced genetic insta-
bility, justifying multiple co-mutations, and by the con-
stant feature of early ASXL1 mutation. To note, none of
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Figure 2. Mutated genes in patients
included in Group 1 (A) and Group 2
(B). (A) All 9 patients of Group 1 pre-
sented at least two mutations. (B) In
Group 2, 13 cases (28%) did not pres-
ent any mutation and are all represent-
ed in the last gray column. Genes are
color coded and every case is repre-
sented in a column.
A
B
the patients with a “pre-CMML”-MDS presented TP53
mutations, which is very rarely found in CMML. This
suggests that the presence of ASXL1mutations and TP53
wild type could be part of this definition of “pre-CMML”
state. Although this kind of progression MDS-to-CMML
is quite rare, further studies involving larger numbers of
these patients should be carried out in order to confirm
whether this kind of evolution is predictable and would,
therefore, justify an earlier start to therapy  in lower risk
MDS with ASXL1 mutations.
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